Verrica Pharmaceuticals (VRCA) risk factors, FY2025 10-K

Risks Related to Our Financial Position and Capital Needs

1. 01We have incurred significant losses since our inception. We expect to incur losses until revenue from YCANTH (VP-102) is sufficient to fund our operations, if ever, and may never achieve or maintain profitability
2. 02We will need substantial additional funding to meet our financial obligations and to pursue our business objectives, including the continued commercialization of YCANTH (VP-102) for the treatment of molluscum as well as the development of YCANTH (VP-102) for the treatment of common warts and VP-315 for the treatment of BCC
3. 03Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
4. 04SEC regulations limit the amount of funds we can raise during any 12-month period pursuant to our shelf registration statement on Form S-3
5. 05We have a limited operating history and limited history of commercialization, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability
6. 06While our financial statements have been prepared assuming that we will continue as a going concern, we do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern

Risks Related to the Development of Our Product Candidates

1. 07If we are unable to successfully develop, receive regulatory approval for and commercialize any product candidates, or experience significant delays in doing so, our business will be harmed
2. 08Clinical product development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates
3. 09We cannot assure you that any clinical trial that we have conducted, are currently conducting, or may conduct in the future will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates
4. 10If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented
5. 11Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials
6. 12Interim "top-line" and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
7. 13Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
8. 14We may not be successful in our efforts to increase our pipeline of product candidates, including by pursuing additional indications for YCANTH (VP-102) and VP-315 or in-licensing or acquiring additional product candidates for other dermatological indications
9. 15We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
10. 16The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed

Risks Related to the Commercialization of Our Product and Product Candidates

1. 17YCANTH (VP-102) for the treatment of molluscum and any of our product candidates that receive marketing approval, may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
2. 18We face substantial competition, which may result in a smaller than expected commercial opportunity and/or others discovering, developing or commercializing products before or more successfully than we do
3. 19In addition, our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than YCANTH (VP-102) or any other product that we may develop
4. 20NCE exclusivity for future product candidates may be unsuccessful
5. 21The success of YCANTH (VP-102) for the treatment of molluscum and our product candidates will depend significantly on coverage and adequate reimbursement or the willingness of patients to pay for these procedures
6. 22Foreign governments also have their own healthcare reimbursement systems, which vary significantly by country and region, and we cannot be sure that coverage and adequate reimbursement will be made available with respect to the treatments in which our products are used under any foreign reimbursement system
7. 23The market for YCANTH (VP-102) for the treatment of molluscum and our product candidates may not be as large as we expect
8. 24Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
9. 25Our business activities involve the use of hazardous materials, which require compliance with environmental and occupational safety laws regulating the use of such materials. If we or our vendors violate these laws, we could be subject to significant fines, liabilities or other adverse consequences

Risks Related to Our Dependence on Third Parties

1. 26We will rely on third parties to conduct our future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials
2. 27We have entered into, and may seek additional, collaborations with third parties for the development or commercialization of our product candidates
3. 28Our ability to generate revenue from these arrangements will depend on our collaborators’ abilities to successfully perform the functions assigned to them in these arrangements
4. 29If we are not able to establish additional collaborations, we may have to alter our development and commercialization plans

Risks Related to Our Intellectual Property

1. 30If we are unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market
2. 31We may enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
3. 32Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our patents
4. 33Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
5. 34We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful
6. 35Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain
7. 36We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties
8. 37We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
9. 38Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them, or that our trade secrets will be misappropriated or disclosed
10. 39Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Legal and Regulatory Compliance Matters

1. 40The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
2. 41We have obtained regulatory approval for YCANTH (VP-102) for the treatment of molluscum; however, YCANTH (VP-102) for the treatment of molluscum and any future product candidates that are approved will remain subject to ongoing regulatory oversight
3. 42Healthcare legislative or regulatory reform measures may have a negative impact on our business and results of operations
4. 43Our business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery and anti-corruption laws

Risks Related to Employee Matters and Managing Our Growth

1. 44Each of our executive officers may currently terminate their employment or service with us at any time. We do not maintain "key person" insurance for any of our executives or employees
2. 45Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements

Risks Related to Ownership of Our Common Stock and Our Status as a Public Company

1. 46The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses
2. 47We have a substantial number of warrants outstanding. The exercise of our outstanding warrants will dilute existing stockholders and could adversely affect the trading price of our common stock
3. 48Sales of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to decline significantly, even if our business is doing well
4. 49Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result
5. 50Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent our other stockholders from influencing significant corporate decisions
6. 51We are a "smaller reporting company" and, as a result of the reduced disclosure and governance requirements applicable to smaller reporting companies, our common stock may be less attractive to investors
7. 52If we fail to maintain proper and effective internal control over our financial reporting, our ability to produce accurate financial statements on a timely basis could be impaired
8. 53We might not be able to utilize a significant portion of our net operating loss carryforwards
9. 54We do not anticipate paying any cash dividends on our common stock in the foreseeable future
10. 55We incur increased costs and demands upon management as a result of being a public company
11. 56We completed a reverse stock split of our shares of common stock, which may reduce and may limit the market trading liquidity of the shares due to the reduced number of shares outstanding and may potentially have an anti-takeover effect
12. 57If we fail to meet all applicable requirements of Nasdaq and Nasdaq determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock and the market price of our common stock could decrease

General Risk Factors

1. 58Unfavorable conditions, including inflationary pressure, in the global economy could negatively affect our operating results
2. 59If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
3. 60Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts